Abstract
This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.
| Original language | English |
|---|---|
| Pages (from-to) | 185-188 |
| Number of pages | 4 |
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2013 Feb |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
}
The effect of oral prostaglandin analogue on painful diabetic neuropathy : A double-blind, randomized, controlled trial. / Shin, S.; Kim, K. J.; Chang, H. J.; Lee, B. W.; Yang, W. I.; Cha, B. S.; Choi, D.
In: Diabetes, Obesity and Metabolism, Vol. 15, No. 2, 02.2013, p. 185-188.Research output: Contribution to journal › Article
TY - JOUR
T1 - The effect of oral prostaglandin analogue on painful diabetic neuropathy
T2 - A double-blind, randomized, controlled trial
AU - Shin, S.
AU - Kim, K. J.
AU - Chang, H. J.
AU - Lee, B. W.
AU - Yang, W. I.
AU - Cha, B. S.
AU - Choi, D.
PY - 2013/2
Y1 - 2013/2
N2 - This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.
AB - This study was performed to assess the efficacy of beraprost sodium (BPS) in painful diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) patients. In this randomized clinical trial, 99 T2DM patients (41% male, age 60±6years) with DPN but without evidence of peripheral artery disease were randomized to receive either BPS (40 μg, tid) or placebo for 8weeks. The primary end point was the improvement of the total symptom score (TSS), temperature rebound (TR) and nadir to peak (NP) above baseline. After 8weeks treatment, the change of TSS in the BPS group showed a significant improvement compared to the placebo group (2.80±2.48 vs. 1.60±1.94 points, p=0.009). Furthermore, the number of patients who showed signs of improvement in TSS and the proportion of patients with 50% relief of symptom was also significantly greater in the BPS group than in the placebo group (83.7 vs. 62%, p=0.015, 36.2 vs. 14%, p=0.009, respectively). In conclusion, treatment with BPS significantly improved TSS over an 8-week period.
UR - http://www.scopus.com/inward/record.url?scp=84871937278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871937278&partnerID=8YFLogxK
U2 - 10.1111/dom.12010
DO - 10.1111/dom.12010
M3 - Article
C2 - 22974254
AN - SCOPUS:84871937278
VL - 15
SP - 185
EP - 188
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 2
ER -